Cyclopharm (ASX:CYC) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CYC Panoramica delle azioni

Cyclopharm Limited produce e vende apparecchiature mediche e radiofarmaci nell'area Asia-Pacifico, in Europa, in Canada e a livello internazionale.

Informazioni sull'azienda

CYC analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 85.9% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 94.87% all'anno

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Cyclopharm Limited Concorrenti

Optiscan Imaging

ASX:OIL

AU$158.7m

ImpediMed

ASX:IPD

AU$117.3m

SomnoMed

ASX:SOM

AU$86.4m

Austco Healthcare

ASX:AHC

AU$88.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Cyclopharm
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$1.47
Massimo di 52 settimane	AU$3.15
Minimo di 52 settimane	AU$1.35
Beta	0.70
1Variazione di 1 mese	6.52%
Variazione a 3 mesi	-13.02%
Variazione di 1 anno	-48.06%
3Variazione a 3 anni	-9.26%
Variazione a 5 anni	22.50%
Variazione dall'IPO	-21.60%

Notizie e aggiornamenti recenti

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Rendimenti per gli azionisti

	CYC	AU Medical Equipment	AU Mercato
7D	2.1%	0.3%	0.3%
1Y	-48.1%	12.3%	16.0%

Ritorno vs Industria: CYC ha avuto una performance inferiore rispetto al Australian Medical Equipment che ha registrato un rendimento 13.1 % nell'ultimo anno.

Rendimento vs Mercato: CYC ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 11.2 % nell'ultimo anno.

Volatilità dei prezzi

Is CYC's price volatile compared to industry and market?
CYC volatility
CYC Average Weekly Movement	5.6%
Medical Equipment Industry Average Movement	9.5%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.6%

Prezzo delle azioni stabile: CYC non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 10% ) di CYC è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1986	87	James McBrayer	www.cyclopharm.com

Cyclopharm Limited produce e vende apparecchiature mediche e radiofarmaci nell'area Asia-Pacifico, in Europa, in Canada e a livello internazionale. L'azienda opera attraverso i segmenti Technegas e Molecular Imaging. Il segmento Technegas offre apparecchiature diagnostiche e materiali di consumo utilizzati dai medici per il rilevamento dell'embolia polmonare.

Cyclopharm Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Cyclopharm con la sua capitalizzazione di mercato?
CYC statistiche fondamentali
Capitalizzazione di mercato	AU$163.37m
Guadagni(TTM)	-AU$9.32m
Ricavi(TTM)	AU$24.06m

6.8x

Rapporto P/S

-17.5x

Rapporto P/E

CYC è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CYC Conto economico (TTM)
Ricavi	AU$24.06m
Costo del fatturato	AU$10.23m
Profitto lordo	AU$13.82m
Altre spese	AU$23.14m
Guadagni	-AU$9.32m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.084
Margine lordo	57.47%
Margine di profitto netto	-38.72%
Rapporto debito/patrimonio netto	0%

Come si è comportato CYC nel lungo periodo?

Vedi performance storica e confronto

CYC Panoramica delle azioni

Premi

Analisi del rischio

Cyclopharm Limited Concorrenti

ASX:OIL

AU$158.7m

ASX:IPD

AU$117.3m

ASX:SOM

AU$86.4m

ASX:AHC

AU$88.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recent updates

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment